Drugs / BERSIPOROCIN
last change Jul 2022 re-read 2 minutes ago

BERSIPOROCIN

Small molecule

Developed for
idiopathic pulmonary fibrosis
Investigated by
Daewoong Pharmaceutical Co. LTD.

Trials 4 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 13 trials
Phase 1 NCT04888715 Jul → Aug 2021 idiopathic pulmonary fibrosis Daewoong Pharmaceutical Co. LTD. Completed No outcome recorded
Phase 1 NCT04888728 Jun → Jul 2021 idiopathic pulmonary fibrosis Daewoong Pharmaceutical Co. LTD. Completed No outcome recorded
Phase 1 NCT04767815 Mar → May 2021 idiopathic pulmonary fibrosis Daewoong Pharmaceutical Co. LTD. Completed No outcome recorded
Phase 21 trial
Phase 2 NCT05389215 Jul 2022 → Oct 2026 expected idiopathic pulmonary fibrosis Daewoong Pharmaceutical Co. LTD. Active not recruiting No outcome recorded

Evidence & citations 9 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as BERSIPOROCIN ChEMBL registry synonym — accepted as the source's own label CHEMBL4802138
Known as BERSIPOROCIN HYDROCHLORIDE ChEMBL registry synonym — accepted as the source's own label CHEMBL4802138
Known as Bersiporocina ChEMBL registry synonym — accepted as the source's own label CHEMBL4802138
Known as Bersiporocine ChEMBL registry synonym — accepted as the source's own label CHEMBL4802138
Known as DWN-12088 HYDROCHLORIDE ChEMBL registry synonym — accepted as the source's own label CHEMBL4802138
Known as DWN12088 “Fasting + DWN12088 200 mg” NCT04767815
3

NCT04888728

NCT04888715

NCT05389215

Action Inhibit “Prolyl-tRNA synthetase (PRS) inhibitor” NCT04888715
Modality Small molecule CHEMBL4802138
Route Oral “single oral dose of DWN12088” NCT04767815